Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23375144 | 0.97 | NR1H4 (0.40) | NR1H4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL31042715 | 0.93 | NR1H4 (0.40) | NR1H4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL31042716 | 0.93 | NR1H4 (0.40) | NR1H4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL23395210 | 0.93 | NR1H4 (0.40) | NR1H4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL23395211 | 0.93 | NR1H4 (0.40) | NR1H4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL23375141 | 0.93 | NR1H4 (0.40) | NR1H4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL23375117 | 0.93 | NR1H4 (0.42) | NR1H4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL23375178 | 0.92 | NR1H4 (0.38) | NR1H4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL23375151 | 0.90 | NR1H4 (0.42) | NR1H4 | |
| SCHEMBL23375135 | 0.90 | NR1H4 (0.42) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024495-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2024-07-02 | — | — | US | disclosed |
| CN-114786773-A | Benzothiazepine compounds and their use as bile acid modulators | 阿尔比里奥公司 | 2022-07-22 | — | — | CN | disclosed |
| US-20210299141-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-09-30 | — | — | US | disclosed |
| US-20210171479-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-06-10 | — | — | US | disclosed |
| WO-2021110887-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-06-10 | — | — | WO | disclosed |
| US-11014898-B1 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2021-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024495-B2 | Benzothiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | NR1H4 6/4885PSEN1 916/4885PSEN2 1023/4885 |
| US-20210171479-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | NR1H4 6/4885PSEN1 922/4885PSEN2 1051/4885 |
| US-20210299141-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | NR1H4 6/4885PSEN1 916/4885PSEN2 1023/4885 |
| US-11014898-B1 | Benzothiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | NR1H4 6/4885PSEN1 916/4885PSEN2 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.